Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-COVID-19 Immune Globulin (Human)
- Development stage
- Discontinued
- Lead developer
- Grifols
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Anti-COVID-19 Immune Globulin (Human) is a 20% solution of human immune globulin, purified from the plasma of convalescent donors who have recovered from COVID-19. Developed by Grifols Therapeutics LLC, this biologic contains high titers of anti-SARS-CoV-2 antibodies. Its primary mechanism of action involves providing passive immunity by neutralizing the SARS-CoV-2 virus, thereby preventing viral entry into host cells. Additionally, it may exert immunomodulatory effects to mitigate inflammation associated with COVID-19. It was investigated for its efficacy in preventing symptomatic COVID-19 in asymptomatic outpatients infected with SARS-CoV-2.
- Other names
- anti-SARS-CoV-2 hyperimmune globulinanti-SARS-CoV2 hyperimmune globulinanti-SARS-CoV 2 hyperimmune globulinanti-SARS-CoV-2 hyperimmune immunoglobulinanti-SARS-CoV2 hyperimmune immunoglobulinanti-SARS-CoV 2 hyperimmune immunoglobulin
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)SARS-CoV-2 spike
Beyond the preview
Go deeper on Anti-COVID-19 Immune Globulin (Human).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-COVID-19 Immune Globulin (Human).